Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002308 · ClinicalTrials.gov registry record · NA

A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs

A NA study of HIV Infections, sponsored by Bristol-Myers Squibb.

Completed
Registry status
NA
Development phase
1
Study location

NCT00002308: Completed NA study of HIV Infections, sponsored by Bristol-Myers Squibb.

NCT00002308 is a NA study of HIV Infections that has completed, run by Bristol-Myers Squibb. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002308, a NA study of HIV Infections, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
NA
Development phase
1
Study location

Study Summary

To make stavudine (d4T) available to patients with advanced HIV disease for whom no alternative antiretroviral is satisfactory. To study the safety and efficacy of two dose levels in a twice-daily regimen.

Conditions Studied

HIV Infections

Interventions

  • DRUG Stavudine

Study Locations (1)

New Jersey

  • Bristol - Myers Squibb Co - Princeton

Trial Details

FieldValue
Est. Completion 1991-11
Phase NA
Bristol-Myers Squibb

1,025 total trials

What the finished NCT00002308 record still lists

NCT00002308 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Stavudine is the first listed.

NCT00002308 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT00002308 about?

NCT00002308 is a clinical study titled "A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs". To make stavudine (d4T) available to patients with advanced HIV disease for whom no alternative antiretroviral is satisfactory. To study the safety and efficacy of two dose levels in a twice-daily regimen.

What is the current status of trial NCT00002308?

This trial is currently completed. It is a NA study. Estimated completion is 1991-11.

What conditions does trial NCT00002308 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002308?

The interventions under investigation include: Stavudine (DRUG).

Who is sponsoring clinical trial NCT00002308?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002308 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00002308, the US trial registry maintained by the National Library of Medicine. NCT00002308 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.